Analytical Data
-
Gene name
IAH1
- Application
-
Species
Saccharomyces cerevisiae
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P41734
-
Expression Region
1-238aa
-
Molecular Weight
34.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The IAH1 protein, a member of the interferon-inducible family, has gained significant attention in recent years due to its potential roles in immune response and viral pathogenesis. Research indicates that IAH1 may be essential in mediating antiviral effects, particularly against various RNA viruses, which has led to investigations into its functional mechanisms. Understanding the structure and dynamics of IAH1 is crucial, as its reconstitution into functional recombinant proteins can provide insights into its biological roles and therapeutic potential. Studies have emphasized the importance of post-translational modifications and interactions with other cellular proteins, suggesting that IAH1 may play a pivotal role in modulating host immune responses. The ability to produce recombinant IAH1 proteins allows researchers to explore these interactions in detail, paving the way for novel therapeutic strategies against infectious diseases. Additionally, the potential application of IAH1 in vaccine development and its utility as a biomarker for disease progression are areas of active exploration. Overall, the study of IAH1 recombinant proteins represents a promising frontier in understanding antiviral immunity and developing innovative clinical applications.
